Nurix Therapeutics Doses First Patient in Phase 1a/1b Study of NX-5948 For B-cell malignancies

Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that the first patient has been dosed in the  Phase 1a/1b study to evaluate orally available small molecule NX-5948, in patients with relapsed B-cell malignancies.

Arthur T. Sands, President and chief executive officer, commented : “Our BTK degraders, NX-2127 and NX-5948, provide potentially complementary solutions to the growing problem of resistance, which has been noted with all BTK inhibitors currently in use and leads to disease relapse”.

The company anticipates initial safety data readout from the Phase 1a portion of the study in the second half of 2022.

Earlier, NX-5948 data readout from the preclinical studies presented at the 2021 American Society of Hematology (ASH) Annual Meeting.

Nurix Therapeutics closed Monday’s trading high at $9.70

Posted In: BiotechNewsHealth CareFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.